MDS Nordion Provides Update on AECL’s Medical Isotope Supply Disruption
AECL has advised MDS Nordion that they anticipate the National Research Universal reactor (NRU) will remain out of service for more than one month. According to a press release issued by AECL on
MDS Nordion expects the impact of this shutdown to begin to be felt this week. The NRU produces approximately 30%-40% of the world’s medical isotopes and approximately 50% of those used in
MDS Nordion recognizes the important role medical isotopes play in the diagnosis and treatment of life-threatening conditions such as heart disease and cancer. The Company continues to work to secure a reliable, long-term supply of medical isotopes. In 1996, MDS Nordion contracted for AECL to complete and commission the MAPLE reactors, which were meant to replace the NRU. This project was unilaterally discontinued in
In addition to MAPLE, MDS Nordion is examining longer-term supply alternatives. One such program is MDS Nordion’s recently announced collaboration with TRIUMF,
Based on this latest update from AECL, MDS Inc. expects the financial impact of this extended interruption to reduce MDS Nordion’s adjusted EBITDA by approximately
Additional background pertaining to today’s announcement can be found on MDS Inc.’s Website at http://www.mdsinc.com/for_media/electronic_media_kit.asp
About MDS Nordion
MDS Nordion, a business unit of MDS Inc., is a global leader in providing medical isotopes for molecular and diagnostic imaging, radiotherapeutics and sterilization technologies for medical products that benefit the lives of millions of people in more than 50 countries around the world. MDS Nordion products and services are used on a daily basis by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Find out more at www.mdsnordion.com
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs, and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,000 highly skilled people in 29 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
This document contains forward-looking statements. Some forward-looking statements may be identified by words like “expects”, “anticipates”, “plans”, “intends”, “indicates”, “targeted” or similar expressions. The statements are not a guarantee of future impact or performance and are inherently subject to risks and uncertainties. The actual impact to the Company of the maintenance shutdown could differ materially from that currently anticipated due to a number of factors, including, the actual timing of a return to full production and other risk factors identified in other documents filed by the Company with Canadian and U.S. securities regulatory authorities from time to time.
SOURCE MDS Nordion